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Cancer pharmacogenomics have contributed a number of important discoveries to
current cancer treatment, changing the paradigm of treatment decisions. Both somatic
and germline mutations are utilized to better understand the underlying biology of
cancer growth and treatment response. The level of evidence required to fully translate
pharmacogenomic discoveries into the clinic has relied heavily on randomized control
trials. In this review, the use of observational studies, as well as, the use of adaptive
trials and next generation sequencing to develop the required level of evidence for clinical
implementation are discussed.
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INTRODUCTION
In the last decade, the use of genomics in oncology significantly
impacted treatment decisions formany patients. Oncologists have
a variety of treatment options; however one patient may expe-
rience serious adverse events whereas another patient receives
no therapeutic effect. Within a population, substantial variation
exists resulting in unpredictable responses. Pharmacogenomics,
the study of the interaction between the genome and clinical drug
response (Monte et al., 2012), evaluates the associations between
drug efficacy and toxicity and variation in drug metabolizing
enzymes, receptors, transporters, and drug targets (Crews et al.,
2012). The main priority of pharmacogenomics is to optimize
treatment by understanding the underlying biological mecha-
nisms and utilizing genomic contributions to treatment response
to predict and individualize therapy and improve treatment out-
comes. Unlike other diseases, cancer genetics must take into
account both acquired (somatic) and inherited (germline) varia-
tion, both of which contribute to the efficacy and safety of a drug.
However to date, integrated studies of germline and somatic vari-
ation have been limited. Somatic mutations are often attributed
to treatment efficacy, whereas germline mutations are used to
identify patients at highest risk of developing serious adverse
events (Gillis et al., 2014). In this review, we will discuss exam-
ples of pharmacogenomicmarkers and differences in the evidence
level required for implementation into clinical care. In addition,
several mechanisms for developing evidence for clinical imple-
mentation and new technologies entering oncology practice will
be discussed.
SOMATIC MUTATIONS AND TARGETED THERAPY
Somatic mutations have highlighted the importance of under-
standing the underlying biology of cancer with discoveries
elucidating the primary genetic changes driving tumorigenesis
providing molecular drug targets. Prospective tumor sequencing
is being increasingly utilized, changing the paradigm of cancer
treatment from site specific cytotoxic treatment, to molecularly
targeted treatment (MacConaill et al., 2011; Ong et al., 2012).
Many drugs are being developed for defined molecular targets
(Simon, 2013), one such example is the use of crizotinib in
anaplastic lymphoma kinase (ALK) positive non-small cell lung
cancer (NSCLC). Tumor DNA sequencing identified two patients
with NSCLC harboring novel ALK rearrangements as crizo-
tinib, a tyrosine kinase inhibitor, moved into clinical trials. Both
patients showed marked response to crizotinib prompting pro-
tocol amendments to prospectively test for ALK rearrangements
throughout clinical development (Ou, 2011; Ou et al., 2012). The
fortuitous discovery of ALK rearrangements during phase I tri-
als of crizotinib restricted development to a subset of patients
relying heavily on rigorous randomized controlled trials with an
appropriate companion diagnostic to select patients. Predictive
testing for biomarkers like ALK reduces unnecessary treatment
in patients that will not respond and helps avoid potentially toxic
effects of treatment (Ong et al., 2012). Molecularly targeted ther-
apies like crizotinib have replaced cytotoxic therapy as standard
of care in several cancer types including breast cancer, NSCLC,
and melanoma (Ong et al., 2012; Gillis et al., 2014). Randomized
clinical trials (RCTs) have been important to modern medicine,
however the shift away from average treatment effects within a
whole population to molecularly defined sub-populations is new
to clinical trial design, and will be discussed later in this review.
GERMLINE MUTATIONS
In oncology, germline mutations play a significant role in the
treatment response to both chemotherapy and targeted anti-
cancer agents. These mutations are often associated with the
pharmacokinetics of a drug contributing to treatment related
www.frontiersin.org April 2014 | Volume 5 | Article 73 | 1
Filipski et al. Pharmacogenomics in oncology care
adverse events experienced by patients (Hertz and McLeod, 2013;
Gillis et al., 2014). In this regard, germline pharmacogenomic
markers can identify patients at highest risk of developing serious
adverse events that could subsequently lead to treatment discon-
tinuation and failure like musculoskeletal pain after treatment
with aromatase inhibitors. Severe musculoskeletal pain has been
reported in up to half of women treated with aromatase inhibitors
contributing to a treatment discontinuation rate of about 10%
(Crew et al., 2007; Henry et al., 2008; Ingle et al., 2010). Ingle et al.
found four single nucleotide polymorphisms (SNPs) mapping to
the T-cell leukemia 1A (TCL1A) gene were associated with the
development of musculoskeletal adverse events in patients receiv-
ing adjuvant aromatase inhibitors (Ingle et al., 2010). Subsequent
functional studies revealed that TCL1A was induced by estrogen
with higher levels of expression in cells with the variant alleles
for these SNPs. Further results suggested an estrogen dependent,
TCL1A SNP-dependent regulation of cytokines, cytokine recep-
tors, and NF-κB transcriptional activity. These SNP-dependent
changes may help to elucidate the pathway involved in muscu-
loskeletal pain following aromatase inhibitor mediated estrogen
deprivation (Liu et al., 2012). The strategy of discovering genetic
variants and studying the underlying biology of the association
is central in pharmacogenomic studies. It outlines a strong bio-
logical basis for the genetic association and provides mechanistic
insight into the biology of the event that could lead to new drug
targets to prevent the toxicity. Pharmacogenomic markers like
TCL1A are extremely important when taken into context with
not only the large number of women that could be exposed to
aromatase inhibitors, but the fact that many of those women
will have long term survival after receiving aromatase inhibitors
and may experience decreased quality of life due to muscu-
loskeletal pain. However, like many pharmacogenomic markers,
TCL1A may never be used in clinical practice because a large
randomized clinical trial will never be completed to study the
association, even though other treatment options are available
and with the understanding of the biology prevention strategies
could be developed.
In addition to adverse events and pharmacokinetics of a
drug, germline mutations may influence drug efficacy. Recently
a germline mutation in the proapoptotic gene BIM was associ-
ated with the resistance to tyrosine kinase inhibitors in chronic
myeloid leukemia (CML) and epidermal growth factor receptor
(EGFR) mutant NSCLC. Identification of this mutation not only
explains some of the poor response seen in patients with CML
treated with imatinib, but also provides biological insight into
different strategies to overcome the resistance that are currently
in preclinical testing (Cheng and Sawyers, 2012; Ng et al., 2012).
Although still in development, BIM is an important reminder that
only focusing on somatic or germline variation investigators can
miss key mutations that affect treatment outcomes.
One of the most well known pharmacogenomic markers is
the association of thiopurine-S-methyltransferase (TPMT) and
mercaptopurine (6-MP). Mercaptopurine is an important com-
ponent of pediatric acute lymphoblastic leukemia (ALL) treat-
ment, and is used in the treatment of some nonmalignant diseases
(Paugh et al., 2011). A variant in the TPMT gene reduces the
function of the enzyme leading to excessive levels of cytotoxic
thioguanine nucleotides (6-TGNs) subsequently leading to an
increased risk of severe myelosuppression (Paugh et al., 2011).
Although a randomized clinical trial has never been done, the
Food and Drug Administration (FDA) agreed that the evidence
was sufficient to mention testing for TPMT deficiency, thus
allowing identification of safe doses of mercaptopurine without
compromising efficacy (Relling et al., 2011). Ample evidence,
including in vitro and retrospective analyses provide support
for the use of TPMT testing in patients receiving mercaptop-
urine to prevent serious treatment induced myelosuppression
(Relling et al., 2011), but the consistent and widespread use of
pre-treatment TPMT testing has not been universally accepted.
STRATEGIES FOR DEVELOPING PHARMACOGENOMIC
EVIDENCE
The field of pharmacogenomics has uncovered an abundance of
actionable and clinically relevant markers including both somatic
(Table 1) and germline (Table 2) mutations. Prospective screen-
ing for predictive pharmacogenomic markers, like TPMT, may
enhance treatment response by reducing the risk of toxicity from
systemic drug concentrations while maintaining the anti-cancer
activity of the drug. However, implementation into clinical prac-
tice has been slow, in part due to contradictory professional
guidelines and recommendations, and differing thresholds for
evidence (Gillis et al., 2014). RCTs have been the gold stan-
dard for evidence in treatment response and genetic testing
and for pharmacogenomic markers like ALK that were discov-
ered during the drug development process RCTs are feasible.
Randomization in experimental studies attempts to control for
biases by balancing factors that affect outcomes across study
groups. However, clinical trials are not always the most feasible
approach for developing evidence due to cost, time constraints,
and the large sample size necessary to complete a trial (Gillis
et al., 2014). Observational studies are more prone to a num-
ber of biases and the potential confounding which may lead to
incorrect results. But these studies offer some advantages over
clinical trials including larger numbers of subjects at an affordable
cost, ability to examine meaningful genomic subgroups, longer
follow-up times, and ability to examine drugs and their inter-
actions with the genome that are used off-label (Dreyer et al.,
2010). Rigorously designed high-quality observational studies can
play a particularly important role in developing evidence for
decision making in cancer pharmacogenomics because they can
relatively quickly generate results that are applicable to real-world
situations and examine long-term risk and benefits. Below we dis-
cuss the use of epidemiologic studies for developing evidence to
support the use of pharmacogenomic tests where RCTs are not
an option.
RETROSPECTIVE OBSERVATIONAL STUDY
Leveraging clinical trial data in a retrospective case-control study,
where all the patients are receiving treatment, the cases and
controls are those affected and unaffected by the outcome of
interest, is a powerful design approach for detecting common
variants associated with phenotypic traits (Ritchie, 2012). These
retrospective analyses have proven successful for both somatic
and germline mutations. Cetuximab, an anti-EGFR monoclonal
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Table 1 | Selected somatic pharmacogenomic markers.
Pharmacogenomic marker Drug (s) Genome Outcome Multi-tumor marker*
ABL Bosutinib, dasatinib, imatinib, nilotinib,
ponatinib
Somatic Efficacy Yes
ALK Crizotinib Somatic Efficacy Yes
BRAF Vemurafenib Somatic Efficacy Yes
EGFR Afatinib, cetuximab, erlotinib, panitumumab,
vandetinib
Somatic Efficacy Yes
FcγR Cetuximab, rituximab, trastuzumab Somatic Efficacy No
HER2 Lapatinib, pertuzumab, trastuzumab,
trastuzumab emtansine
Somatic Efficacy No
KRAS Cetuximab, panitumumab Somatic Efficacy Yes
KIT Imatinib Somatic Efficacy Yes
MET Trametinib Somatic Efficacy Yes




Table 2 | Selected germline pharmacogenomic markers.
Pharmacogenomic marker Drug (s) Genome Outcome Multi-tumor marker*
BIM Imatinib Germline Efficacy No
CYP2B6 Cyclophosphamide Germline Toxicity No
CYP2D6 Tamoxifen Germline Efficacy No
DPYD Capecitabine, fluorouracil Germline Toxicity No
G6PD Rasburicase Germline Toxicity No
MLH1, MSH2, MSH6, PMS2 Fluorouracil Germline Efficacy Yes
SLCO1B1 Methotrexate Germline Toxicity No
SLC28A3 Anthracyclines Germline Toxicity No
TCL1A Aromatase inhibitors Germline Toxicity No
TPMT Mercaptopurine, thioguanine, cisplatin Germline Toxicity No
UGT1A1 Irinotecan Germline Toxicity No




antibody is used in the treatment of colorectal cancer, however
only a subset of patients responded to treatment. Tumor samples
from cetuximab treated patients were retrospectively analyzed
identifying mutations in the KRAS gene that were associated with
response to therapy (Karapetis et al., 2008; Van Cutsem et al.,
2009). Patients that are mutation positive do not respond to
cetuximab, leading to the development of a companion diagnostic
for KRAS testing and changes to the prescribing information for
cetuximab to only be used in KRAS mutation negative patients.
Although only retrospective analyses were performed, profes-
sional societies and the FDA recommend KRAS testing prior to
initiation of cetuximab therapy (Kelley et al., 2011; Evaluation
of Genomic Applications in Practice and Prevention Working
Group, 2013).
ELECTRONIC MEDICAL RECORDS
The electronic medical record (EMR) provides a wealth of
information to study questions at the population level. Large
patient cohorts can be quickly created for a variety of diseases
and drug response phenotypes to better evaluate drug safety.
With the establishment of biobanks concurrent with the adoption
of EMR, studies of genomic associations of drug response may
become more comprehensive. The NHGRI funded Electronic
Medical Records and Genomics (eMERGE) Network is leading
the way by developing best practices for EMR guided genomic
studies (Gottesman et al., 2013). These population based stud-
ies have access to much larger populations of patients making it
easier to study rare, but serious, adverse events. One eMERGE
site, Marshfield Clinic Personalized Medicine Project (PMRP),
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identified genetic factors associated with thromboembolic events
in women taking tamoxifen. Patients were identified for a study
by interrogating the EMR for breast cancer diagnosis, tamox-
ifen treatment, and thromboembolic event. SNPs in the ESR1
gene were shown to be associated with thromboembolic events
in women treated with tamoxifen. These events are relatively
rare (1.7–8.4%) therefore using this large practice based cohort,
investigators were able to capture enough events to evaluate
the underlying genetic difference in women with and without
thromboembolic events (Onitilo et al., 2009).
EMR based studies provide some advantages over RCTs in
evaluating drug safety in the general population. Biobanks of sev-
eral sites can participate together in investigations, thus increasing
sample size and study power. In addition, clinical trials exclude
patients with comorbidities, taking concomitant medications,
andmay include run in periods excluding patients that show drug
intolerance prior to randomization. In the unrestricted EMRpop-
ulations a higher incidence of adverse events may be identified
(Wilke et al., 2011).
EMERGING TECHNOLOGIES AND TRIAL DESIGN
In addition to retrospective analyses and EMR studies to develop
evidence for the use of pharmacogenomic tests in clinical prac-
tice, the acceptance of new technologies and clinical trial designs
are imperative to improving clinical outcomes. Both the time
and cost of genotyping has been steadily decreasing allowing
for the creation of denser genotyping panels and advent of next
generation sequencing (NGS) has allowed for a more complete
view of the genome. There are three types of NGS: whole exome
sequencing, whole genome sequencing, and targeted gene pan-
els (Rehm et al., 2013). Unlike genotyping of candidate genes
and genome wide association studies, WGS can identify rare vari-
ants that may be very important in the genomic contribution to
treatment response and toxicity (Gillis et al., 2014), particularly
for a drug like methotrexate that has wide inter-individual dif-
ferences. A GWAS identified SNPs annotated to the transporter
gene, SLCO1B1 that were associated with methotrexate clearance
(Trevino et al., 2009). Deep resequencing of the gene was done
and Ramsey et al. found that rare variants, only identified through
deep sequencing accounted for 17.8% of the genes effect on clear-
ance (Ramsey et al., 2012). NGS can provide not only common
variants, but a comprehensive catalog of rare variants that may
have a larger effect size than common variants contributing to
the overall phenotype of drug response (Gillis et al., 2014). There
are some challenges with NGS, particularly the daunting task of
handling and interpreting NGS results.
With the advent of molecularly targeted therapies, prospec-
tive use of NGS is being incorporated into adaptive clinical trials,
using the genomic landscape of the tumor to direct therapy as
opposed to site specific treatment (MacConaill et al., 2011; Ong
et al., 2012). Trials such as the National Cancer Institute’s MPACT
trial are prospectively evaluating tumor mutations for actionable
variants and then randomizing patients to receive a drug targeting
the aberrant pathway or standard of care regardless of tumor site
(Simon and Polley, 2013). Forward thinking trials like MPACT
are poised to change the way tumors are classified and patients
are treated. Already targeted gene panels have emerged focused
on a limited set of genes creating a greater depth of coverage and
improving the ability to interpret the findings in the clinic (Rehm
et al., 2013). Commercially available multi-tumor marker panels
are primarily focused on somatic mutations with the inclusion of
several known driver mutations predictive of treatment response
to molecularly targeted therapies (Table 1), however to date, it is
unknown how comprehensive these panels are, whether they are
including the optimal set of genes, and the broader utility of these
panels has yet to be evaluated. There are challenges and limita-
tions to the use of NGS, but NGS and multi-marker tumor panels
may provide an opportunity to generate incredible amounts of
information about the tumor genome and thus drive research
to elucidate some of the biological mechanisms underlying the
tumor growth and survival.
CONCLUSION
Pharmacogenomics has provided significant impact in oncol-
ogy treatment, but implementation differs between somatic and
germline markers. Developing sufficient evidence for use of phar-
macogenomic markers has been difficult, in part because RCTs
cannot be performed for every marker identified. A move toward
retrospective analyses, large population studies using EMRs,
and the establishment of mechanism-based evidence can propel
progress in the field. In addition, embracing newmethods, such as
NGS and adaptive clinical trials, is providing a wealth of informa-
tion about tumor biology and changing the landscape of cancer
treatment. To date, pharmacogenomic studies tend to focus on
either somatic or germlinemutations in isolation from each other,
but to truly optimize clinical care both genomes need to be inte-
grated into clinical decision making. Both well designed, forward
thinking trials and population based studies are necessary to fully
implement pharmacogenomics into clinical care.
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